Description
Product overview
IGF-1 LR3 (Long R3 Insulin-like Growth Factor 1) is an 83 amino-acid analogue of native IGF-1 with two engineered modifications: a 13 amino-acid N-terminal extension and an arginine substitution at position 3. Supplied as 1mg lyophilised per vial.
Engineering and rationale
The N-terminal extension and Arg-3 substitution sharply reduce binding to IGF binding proteins (IGFBPs). Native IGF-1 circulates ~95% bound to IGFBPs, limiting free fraction. IGF-1 LR3 escapes most IGFBP sequestration, achieving a plasma half-life of approximately 20–30 hours versus ~10–15 minutes for free native IGF-1.
Research mechanism
- IGF-1 receptor (IGF-1R) activation with reduced IGFBP modulation
- Downstream PI3K/Akt and Ras/MAPK signalling cascades
- Minor insulin receptor cross-reactivity at high concentrations
Research applications
- IGF-1 signalling pharmacology with reduced binding-protein confound
- Sustained IGF-1R activation models
- Muscle cell hypertrophy research
- Tissue growth and regeneration studies
Reconstitution and storage
IGF-1 LR3 is best reconstituted with acetic acid solution (0.6% v/v) followed by dilution to working concentration in bacteriostatic water — the acidic step solubilises the lyophilised peptide. Working concentrations of 100–500 µg/mL are typical for stability studies. Refrigerate (2–8°C), stable approximately 4 weeks after reconstitution.
Quality and analytics
HPLC purity ≥98%. Batch-specific Certificate of Analysis with mass spectrometry confirmation available on request.
For laboratory research use only. Not for human or veterinary use.
